A once-weekly prophylactic dose of azithromycin does not improve lung function in children with HIV-associated chronic lung disease (HCLD), according to results of the BREATHE* trial. However, azithromycin was associated with a reduction in acute respiratory exacerbations (AREs).
Altered gut microbiota composition in patients with coronavirus disease 2019 (COVID-19) compared with controls is linked to COVID-19 severity and may contribute to persistent symptoms after viral clearance, according to a study by the Chinese University of Hong Kong (CUHK).
The combination of baricitinib and remdesivir improved recovery time and clinical status of patients with COVID-19 compared with remdesivir monotherapy, results of the ACTT*-2 study showed.
Switching to a telemedicine-only strategy from face-to-face visits does not affect asthma control in children. Moreover, the strategy may actually increase show rates, according to a study presented at the recent ACAAI 2020 meeting.
The elevations in liver enzymes that occur in patients with COVID-19 may be due to other conditions and not as a direct result of COVID-19, according to a poster presented at the AASLD 2020 Liver Meeting.
Adjunctive daptomycin in addition to standard-of-care (SoC) treatment does not reduce the duration of bloodstream infections caused by methicillin-susceptible Staphylococcus aureus (MSSA), according to the DASH* study presented at ID Week 2020.
People with HIV (PWH) who are hospitalized due to COVID-19 may have an increased mortality risk, according to a study from the UK.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.